MD Pharmaceutical

MD Pharmaceutical (Beijing MD Pharmaceutical Technology) is a clinical-stage biopharmaceutical company based in Beijing, China, focused on the discovery and development of innovative small molecule drugs for metabolic and inflammatory diseases. The company's lead program, MD-001, is a highly selective thyroid hormone receptor beta (THR-β) agonist currently in Phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH). MD Pharmaceutical leverages its proprietary structure-based drug discovery platform to target unmet medical needs in chronic liver diseases and other metabolic disorders. The firm is supported by prominent venture capital investors and maintains a robust pipeline of candidates targeting high-potential metabolic pathways. Its global development strategy includes clinical trials and regulatory filings in both China and the United States.